Huntington's Disease Condensate Therapy Cluster
CLOSED 10 September 2026 — this package should not be executed, and the figures below are kept for the record. It proposed a mechanism for mHTT toxicity (liquid-liquid phase separation creates condensates that sequester transcription factors) and a drug strategy following from it (dissolve the condensates with BET bromodomain inhibitors, JQ1 and OTX015, to restore transcription factor availability). Two things went against it. The critical concentration C* ≈ 3.5 µM is a two-point calibration fitted to published data rather than a prediction, and reaching the −44.7% striatal expression deficit it was offered to explain would require the mHTT phase to occupy 16–31% of nuclear volume against 0.4–3.8% at plausible values. Then the tissue: in GSE3790 HD caudate, BDNF and PGC-1α — the Phase 3 readout of this very package, and the genes that would separate sequestration from ordinary medium-spiny-neuron loss — are flat at every Vonsattel grade including grade 0, while the MSN markers PPP1R1B and DRD2 fall as cell loss alone predicts. The earlier claim here that the mechanism was wholly novel with no prior art was never the problem; having no downstream footprint is.
0/2 confirmed
Hypotheses
0
GPU hours
$95k–$280k
Cost range
196 days
Critical path
Combined Impact if Confirmed
Recorded as originally written, and it no longer describes an available outcome. It read: if H₁ is confirmed (mHTT condensates sequester TFs at C* ≈ 3.5 µM) the co-partitioning mechanism is established as a distinct and quantitatively significant mode of mHTT toxicity, and if H₂ is confirmed (≥30% FRAP reduction by JQ1 or OTX015) a CNS-penetrant BET inhibitor with existing Phase I/II human safety data can be repositioned for HD under an accelerated IND. Neither branch is open. H₁’s quantitative conjunct fails by an order of magnitude on nuclear volume fraction, and H₂ was a rescue of H₁’s mechanism, so there is nothing left for it to rescue. The unmet need is real — no approved disease-modifying therapy, ~30,000 US patients — which is why the closure is worth stating plainly rather than leaving this package to read as shovel-ready.
Aggregated Resource Requirements
| Paper | Timeline | GPU hrs | CPU hrs | Mem (GB) | Cost min | Cost max |
|---|---|---|---|---|---|---|
| mHTT Condensates and TF Sequestration in HD This programme is NOT open for execution and the costings below are kept for the record only. The Phase 3 endpoint is BDNF and PGC-1α mRNA rescue, and those two genes do not move in GSE3790 HD caudate at any Vonsattel grade, including grade 0 — so the readout the protocol depends on is absent in human tissue before any compound is applied. Phase 1 (in vitro FRAP, 4 weeks, ~$15k–25k) would still be the lowest-cost gate if the line were ever reopened, and it would test condensate dissolution only, not the transcriptional claim. 0/2 hypotheses confirmed | 196d | — | 80 | 16 | $95k | $280k |
| Combined total | 28–196d | 0 | 80 | 16 | $95k | $280k |
Jun 27, 2026
196 days
Timeline
—
GPU hours
80
CPU hours
16 GB
Memory
$95k
Budget (min)
$280k
Budget (full)
Required Datasets
Phase 1: Recombinant mHTT exon 1 (Q23, Q46, Q72); JQ1 (Cayman 11187), OTX015 (Selleckchem S7360), mitoxantrone (Sigma M6545); confocal microscope with FRAP module. Phase 2: HEK293 cells; mHTT exon 1 Q46-EGFP and Q23-EGFP constructs; anti-SP1, anti-CBP/p300 antibodies for co-IP and immunofluorescence. Phase 3: Q175 knock-in mouse primary striatal neurons or HD iPSC-derived neurons (Coriell GM04281); the active condensate-dissolving compound from Phase 1; RT-qPCR for BDNF and PGC-1α.
Experimental Protocol
Phase 1 (4 weeks): Recombinant Q23/Q46/Q72 mHTT exon 1 purified; condensates formed at 5 µM. Test JQ1, OTX015, mitoxantrone at 0.1, 1, 10, 100 µM. FRAP half-life at 488 nm. Success: ≥1 compound achieves ≥30% FRAP reduction in Q46 at ≤10 µM, no effect on Q23.
Phase 2 (8 weeks): HEK293 cells transfected with Q46-EGFP and Q23-EGFP. Co-IP of SP1 and CBP/p300 with mHTT under compound treatment (active compounds from Phase 1). Success: ≥50% reduction in co-IP, ≥1.5-fold nuclear:cytoplasmic ratio increase by immunofluorescence.
Phase 3 (16 weeks): the active condensate-dissolving compound from Phase 1 applied to Q175 KI mouse striatal neurons or HD iPSC neurons. Endpoints: BDNF and PGC-1α mRNA (RT-qPCR), cell viability (MTT) at 28 days.
Success Criteria
Phase 1: ≥1 compound achieves FRAP half-life reduction ≥30% in Q46 condensates at ≤10 µM; no effect on Q23 (polyQ-specificity). Phase 2: ≥50% reduction in SP1/CBP/p300 co-IP with mHTT Q46 under active compound vs. vehicle; nuclear:cytoplasmic ratio ≥1.5-fold increase. Phase 3: BDNF mRNA rescue ≥20% in the condensate-dissolving arm.
Failure Criteria
Phase 1: No compound achieves ≥30% FRAP reduction at ≤10 µM — H₂ falsified for this compound class. Phase 2: Co-IP unchanged, nuclear localisation unchanged — condensate dissolution does not restore TF availability. Phase 3: No rescue in either monotherapy arm — one or both upstream mechanisms not operating in neuronal model.
Abort Checkpoints
Phase 1, Week 2: Abort if no compound achieves ≥10% FRAP reduction at 100 µM. Phase 2, Week 4: Abort if recombinant condensates do not form at 5 µM Q46. Phase 3, Week 8: Abort if primary neurons show <10% viability under the condensate-dissolving compound at target dose.
Commercial ROI
OTX015/birabresib is CNS-penetrant with completed Phase I/II oncology trials (NCT01713582) — if H₂ is confirmed, an HD repositioning IND can leverage the existing safety dossier. Combined BD value: 30,000 HD patients in the US (no approved DMT); comparable neurodegeneration asset deals ~$1B+.
Research ROI
First direct experimental test of condensate co-partitioning as a mechanism for mHTT toxicity (vs. stoichiometric binding). Confirmation of H₂ would establish a new therapeutic modality (condensate dissolution) for HD and potentially other polyQ diseases (SCA, SBMA).
Hypotheses
mHTT exon 1 at HD-length polyQ (≥Q40) undergoes LLPS at physiologically relevant concentrations (C* ≤ 5 µM in HD striatal neurons) and the resulting condensate phase sequesters transcription factors SP1, CBP/p300, and TFIID/TAF4 by thermodynamic co-partitioning, quantitatively contributing to the observed gene expression deficits in HD striatum.
Compounds with published condensate-disrupting activity in BRD4-containing super-enhancer condensates — specifically BET bromodomain inhibitors (JQ1, OTX015) and mitoxantrone analogues — will reduce the FRAP half-life of mHTT exon 1 Q46 condensates by ≥30% at concentrations ≤10 µM in a validated in vitro assay, and restore SP1/CBP/p300 nuclear availability in HD neuronal models.
Source discoveries on solver.press
All hypotheses in this cluster were sourced from AegisMind discoveries. Each discovery carries its own EVP, adversarial debate score, and formal verification status — click any hypothesis above to view it.
Browse all discoveries →